Alnylam Pharmaceuticals
ALNY
#788
Rank
C$44.37 B
Marketcap
C$331.66
Share price
3.63%
Change (1 day)
-48.57%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$7.71

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$7.88. In 2025 the company made an earnings per share (EPS) of C$2.94.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$7.71162.64%
2025C$2.94
2023C-$5.03-62%
2022C-$13.2429.03%
2021C-$10.26-3.36%
2020C-$10.62-8.48%
2019C-$11.607.67%
2018C-$10.7839.74%
2017C-$7.7112.94%
2016C-$6.8338.84%
2015C-$4.92-32.88%
2014C-$7.33259.44%
2013C-$2.04-31.25%
2012C-$2.96

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$9.49 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$2.71-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$59.74 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$3.75-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.04-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.13-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$0.90-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C-$4.75-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA